Fayetteville, AR, United States
Fayetteville, AR, United States

Time filter

Source Type

News Article | November 7, 2016
Site: co.newswire.com

Highlands Oncology Group Centers Are First In World to Conduct Trial on PDL-1 Immunotherapy and Radiation for Initial Head and Neck Cancer Treatment Highlands Oncology Group (HOG), Northwest Arkansas’ leading cancer research group, is the first cancer treatment group, globally, to open a new clinical trial which studies the use of PDL-1 immunotherapy in combination with radiation as the inaugural therapy for head and neck cancer. “Highlands is excited to be the first institute to open this global effort to bring immunotherapy to the forefront of care for patients in our community,” Dr. J. Thaddeus Beck, of HOG, said. “This program is an extension of our phase one development.” Cancers of the head and neck, which include cancers of the oral cavity, larynx, pharynx, salivary glands, and nose/nasal passages, account for approximately three percent of all malignancies in the United States, according to the National Cancer Institute. Tobacco and alcohol use are the most important risk factors for most head and neck cancers. In 2016, there will be an estimated 1,685,210 new cancer cases diagnosed and 595,690 cancer deaths in the U.S., according to the American Cancer Society. As such, HOG is committed to the betterment of cancer treatment. As the leading cancer treatment and research facility in Northwest Arkansas, Highlands Oncology Group is dedicated to the advancement of cancer treatment and to providing patients with the best possible care and results. Highlands Oncology Group is a state-of-the-art facility, with a world-class team of specialists, that is committed to providing premier cancer treatment and to enhancing the quality of life of patients and their loved ones. Highlands Oncology group provides this in a friendly, comfortable environment conveniently located in Northwest Arkansas. Highlands offers the latest technology of diagnostic imaging and radiation therapies, on-site labs, a pharmacy and an infusion center. They also offer access to clinical trials, multidisciplinary clinics and support groups. Highlands Oncology Group is helping patients win the battle against cancer, every day! For more information, please visit: www.HighlandsOncologyGroup.com.


Highlands Oncology Group Collaborated on Study of Breast Cancer Recurrence


News Article | October 28, 2016
Site: co.newswire.com

On September 27th, 2016 Highlands Oncology Group Will Host Free Prostate Cancer Screenings in Collaboration With The Arkansas Prostate Cancer Foundation


Highlands Oncology Group Will Collaborate To Research Immunotherapy For Ovarian Cancer


News Article | December 9, 2016
Site: co.newswire.com

Highlands Oncology Group Physician Voted "Best Oncologist" in Northwest Arkansas


Beck J.T.,Highlands Oncology Group | Ismail A.,University of Arkansas for Medical Sciences | Tolomeo C.,University of Arkansas for Medical Sciences
Cancer Treatment Reviews | Year: 2014

Squamous cell lung carcinoma accounts for approximately 30% of all non-small cell lung cancers (NSCLCs). Despite progress in the understanding of the biology of cancer, cytotoxic chemotherapy remains the standard of care for patients with squamous cell lung carcinoma, but the prognosis is generally poor. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is one of the most commonly activated signaling pathways in cancer, leading to cell proliferation, survival, and differentiation. It has therefore become a major focus of clinical research. Various alterations in the PI3K/AKT/mTOR pathway have been identified in squamous cell lung carcinoma and a number of agents targeting these alterations are in clinical development for use as single agents and in combination with other targeted and conventional treatments. These include pan-PI3K inhibitors, isoform-specific PI3K inhibitors, AKT inhibitors, mTOR inhibitors, and dual PI3K/mTOR inhibitors. These agents have demonstrated antitumor activity in preclinical models of NSCLC and preliminary clinical evidence is also available for some agents. This review will discuss the role of the PI3K/AKT/mTOR pathway in cancer and how the discovery of genetic alterations in this pathway in patients with squamous cell lung carcinoma can inform the development of targeted therapies for this disease. An overview of ongoing clinical trials investigating PI3K/AKT/mTOR pathway inhibitors in squamous cell lung carcinoma will also be included. © 2014 Elsevier Ltd.


Highlands Oncology Group Proudly Congratulates Nurses on Achieving Certification in Oncology Nursing


News Article | October 28, 2016
Site: co.newswire.com

Highlands Oncology Group Prepares For Race For The Cure 2016


News Article | October 28, 2016
Site: co.newswire.com

Highlands Oncology Group Physician Collaborated On Research To Be Published


News Article | October 28, 2016
Site: co.newswire.com

Highlands Oncology Group is Excited to Welcome Dr. Juan Lombeida to the Team

Loading Highlands Oncology Group collaborators
Loading Highlands Oncology Group collaborators